ITOS insider converts RSUs to $10.047 cash plus CVR in Concentra merger
Rhea-AI Filing Summary
iTeos Therapeutics insider reporting linked to merger consideration
David Feltquate, Chief Medical Officer of iTeos Therapeutics (ITOS), reported a disposition on 08/29/2025 of 47,000 restricted stock units that became vested and were canceled under the Agreement and Plan of Merger with Concentra Biosciences LLC. In exchange for canceled units, holders were entitled to $10.047 in cash per share (subject to tax withholding) and one non-transferable contractual contingent value right per share. The Form 4 shows the reporter held 0 shares following the transaction. The filing was signed by an attorney-in-fact, Adi Osovsky.
Positive
- Recipients received cash consideration of $10.047 per share for canceled restricted stock units
- Holders also received one non-transferable contingent value right per share, preserving potential upside beyond the cash payment
Negative
- Reporting person’s beneficial ownership reduced to 0 shares following the merger-related cancellation
- 47,000 restricted stock units were canceled, eliminating future equity upside tied to those units for the reporting person
Insights
TL;DR: Insider equity awards were accelerated and converted to merger consideration, eliminating reported holdings.
The filing documents a routine merger-related accelerated vesting and cash-out of time-based restricted stock units for an executive. From a governance perspective, the Compensation and Leadership Development Committee approved treatment consistent with the Merger Agreement, converting vested awards into cash and contingent value rights. This is a standard exit treatment that aligns executive compensation outcomes with transaction terms; it reduces insider equity exposure post-close and crystallizes value for award holders.
TL;DR: Transaction reflects customary merger mechanics: tender/merger, accelerated vesting, cash consideration plus CVRs.
The Form 4 confirms that the Merger Agreement provided for accelerated vesting of qualifying restricted stock units, cancellation of those units, and payout of specified cash consideration of $10.047 per share plus one contingent value right per share. This treatment is consistent with a cash-centric purchase with retained contingent upside via CVRs and illustrates how equity-based compensation was settled at close.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| U | Common Stock | 47,000 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company and thereafter, the Merger Sub merged with and into the Company (the "Merger"). The amount reported in Column 4 includes 47,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit"). (Continued from footnote 1) Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit") (Continued from footnote 2) that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to $10.047 in cash per share and (y) one non-transferable contractual contingent value right per share.
